IRABCS
https://irabcs.com
INNOVATIVE RESEARCH IN APPLIED, BIOLOGICAL AND CHEMICAL SCIENCES
ISSN: 3005-8449

Research Article

IRABCS, vol. 2, issue 2, pp. 254-259, 2024
Received: July 26, 2024
Revised: August 15, 2024
Accepted: September 22, 2024
https://doi.org/10.62497/IRABCS.2024.65

Understanding the Mechanisms of Drug Resistance in Non-Small Cell Lung Cancer Potential Therapeutic Approaches

Afnan Ali Shah[1], Waqar Ahmad Tahir[2], Owais Nawaz Khan[3*], Ayesha Abid[4], Yasar Umar Khan[5] and Talha Mazhar[5]

1. *MBBS, Bannu Medical College, Bannu, Pakistan*
2. *ECFMG Certified, Medical Officer, Khalifa Gull Nawaz Teaching Hospital MTI, Bannu, Pakistan*
3. *MBBS, Khyber Medical College, Peshawar, Pakistan*
4. *MBBS, Nowshera Medical College, Nowshera, Pakistan*
5. *MBBS, Saidu Medical College, Swat, Pakistan*
6. *E-mail any correspondence to: owaisnawaz.khan@kmc.edu.pk*

How to cite: Ali Shah A, Tahir WA, Khan ON, Abid A, Khan YU, Mazhar T. Understanding the Mechanisms of Drug Resistance in Non-Small Cell Lung Cancer Potential Therapeutic Approaches. IRABCS. 2024. vol. 2, issue 2, pp. 254-259. https://doi.org/10.62497/IRABCS.2024.65. Available from: https://irabcs.com/ojs/article/view/65

Abstract

Background: Drug resistance is a major obstacle to the successful treatment of non-small cell lung cancer (NSCLC), the most common subtype of lung cancer. The aim of this research was to explore potential treatment strategies and the mechanisms underlying drug resistance in non-small cell lung cancer.

Methodology: From March 2022 to February 2024, a prospective observational research was carried out at Lady Reading Hospital in Peshawar. 128 NSCLC patients in all were enrolled. Next-generation sequencing, DNA methylation tests, and immunological profiling were used to examine the genetic, epigenetic, and environmental components linked to medication resistance. Multivariate logistic regression, t-tests, chi-square tests, and Kaplan-Meier survival analysis were among the statistical techniques used.

Results: T790M mutations contributed to resistance, with EGFR mutations found in 35% of patients. Ten percent of patients had MET amplifications, while seven percent of patients had ALK rearrangements. In resistant cancers, epigenetic changes such as hypoacetylation of histones and hypermethylation of CDKN2A were common. Immunosuppressive cells and cancer-associated fibroblasts were abundant in the tumor microenvironment. The median overall survival (OS) of patients with drug-resistant NSCLC was 14 months, a substantial decrease from the 22 months seen in patients without resistance ($p < 0.001$).

Conclusions: The research emphasizes how genetic, epigenetic, and microenvironmental variables all play a role in the complex process of medication resistance in non-small cell lung cancer. Molecular profiling and targeted medicines along with personalized treatment techniques are critical to overcome resistance and enhancing patient outcomes. Larger, more varied populations and the creation of cutting-edge treatment approaches should be the main topics of future study.

Keywords: cell lung cancer, drug resistance, EGFR mutations, epigenetic modifications, tumor microenvironment, personalized therapy

Introduction

The most common subtype of lung cancer is non-small cell lung cancer (NSCLC), which makes up around 85% of all instances of lung cancer [1]. In spite of tremendous progress in early diagnosis and treatment approaches, NSCLC continues to be the primary cause of cancer-associated death globally [2]. For NSCLC, conventional treatment plans include of radiation, chemotherapy, surgery, and targeted treatments. Nonetheless, the emergence of medication resistance poses a significant obstacle to efficient therapy, resulting in the advancement of the illness and an unfavorable outlook [3-5]. Primary (intrinsic) and acquired resistance are the two major categories of drug resistance in NSCLC [6]. Primary resistance denotes the cancer cells' innate insensitivity to therapeutic medicines, while acquired resistance emerges after a brief window of susceptibility [7, 8]. The underlying causes of medication resistance in NSCLC are complex and include genetic, epigenetic, and microenvironmental variables [9-11].

Effective therapy methods for NSCLC need an understanding of the processes behind drug resistance. Drug resistance has been linked to a number of genetic changes, including KRAS mutations, rearrangements in the anaplastic lymphoma kinase (ALK) gene, and mutations in the epidermal growth factor receptor (EGFR) gene [12]. Resistance to EGFR tyrosine kinase inhibitors (TKIs) has also been linked to changes in the MET gene and overexpression of the MET receptor tyrosine kinase [13]. Drug resistance is also significantly influenced by epigenetic changes like DNA methylation and histone acetylation. These alterations may result in the activation of oncogenes and the silencing of tumor suppressor genes, which would increase the survival and growth of cancer cells. Moreover, the tumor microenvironment may affect treatment response and resistance. This includes immune cells, extracellular matrix components, and cancer-associated fibroblasts [14].

Combination therapies, which target many drug resistance pathways, have been shown to be a viable strategy for overcoming this obstacle in recent study. Preclinical and clinical research are now being conducted to investigate novel treatment approaches, such as the use of immune checkpoint inhibitors, anti-angiogenic drugs, and inhibitors of certain resistance pathways. With an emphasis on genetic, epigenetic, and microenvironmental variables, this research attempts to give a thorough assessment of the processes behind treatment resistance in (NSCLC). We will also go over possible treatment strategies for overcoming drug resistance, stressing the most recent developments and promising paths for the sector. Our goal is to open the door for the creation of more individualized and potent therapies for NSCLC patients by clarifying the intricate interactions between the many elements that lead to drug resistance.

Materials and methods

Study Design and Location

The Lady Reading Hospital (LRH) in Peshawar, Pakistan, served as the study's site. The research was planned to be a prospective observational one, running from March 2022 to February 2024. The objective was to assess prospective treatment options to overcome medication resistance in individuals diagnosed with NSCLC and to look into the mechanisms behind this resistance.

Sample Size Calculation

Based on the expected incidence of medication resistance and the frequency of non-small cell lung cancer, the study's sample size was determined. It was shown that a minimal sample size of 128 patients would be adequate to generate statistically significant findings, using a 95% confidence level and a 5% margin of error. In order to provide sufficient power to identify variations in outcomes across subgroups, the sample size calculation additionally took the projected dropout rate and non-compliance into account.

Patient Selection and Recruitment

Study participants were to be receiving treatment at LRH and have a diagnosis of NSCLC. Patients with histologically proven NSCLC who were at least eighteen years old and had undergone at least one course of systemic treatment met the inclusion criteria. The trial excluded patients who were incapable of giving informed permission or who had other concomitant cancers as these conditions could confound the study outcomes. Prior to recruitment, qualified patients were contacted and their informed permission was acquired.

Data Collection

A thorough examination of each patient's medical record, including demographic data, clinical traits, treatment plans, and therapeutic response, was necessary for data gathering. Samples of tumors were taken both at the beginning and as the illness progressed in order to evaluate the genetic, epigenetic, and environmental components linked to medication resistance. Next-generation sequencing (NGS) and other molecular investigations were used to find mutations in important genes including EGFR, ALK, KRAS, and MET. Using the proper assays, epigenetic changes, such as DNA methylation and histone acetylation patterns, were also examined.

Treatment and Follow-up

Patients had surgery, chemotherapy, radiation therapy, and targeted treatments as part of standard-of-care care, which was determined by the most recent clinical recommendations. Based on the molecular features of the patients' tumors and their clinical profiles, a customized treatment plan was established. Regular follow-up evaluations were carried out to track the development of drug resistance, the course of the illness, and the response to therapy. Statistical Analysis: Version 26.0 of the SPSS program was used to conduct the statistical analysis. The research population's clinical and demographic features were compiled using descriptive statistics. The relationship between medication resistance and genetic, epigenetic, and microenvironmental variables was assessed by multivariate logistic regression analysis, t-tests, and chi-square tests. To estimate progression-free and overall survival, Kaplan-Meier survival curves were created, and the log-rank test was used to compare the survival distributions of the groups. Less than 0.05 was the threshold for statistical significance.

Results

The patients' male to female ratio was 1.5:1, and their median age ranged from 37 to 79 years. The majority of patients (74%) smoked either now or in the past. Table 1 illustrates the most prevalent histological subtype, which was adenocarcinoma, which accounted for 60% of cases. Squamous cell carcinoma (30%) and large cell carcinoma (10%) followed.

Table 1: Patient Demographics and Clinical Characteristics

Characteristic		Value (n=128)
Median Age (years)		62 (range 37-79)
Male-to-Female Ratio		1.5:1
Smoking Status	Current/Former Smokers	74%
	Non-Smokers	26%
Histological Subtype	Adenocarcinoma	60%
	Squamous Cell Carcinoma	30%
	Large Cell Carcinoma	10%

Next-generation sequencing (NGS) has revealed a number of significant genetic alterations linked to NSCLC treatment resistance. Three-quarters of the patients had EGFR mutations; exon 19 deletions and the L858R point mutation were the most prevalent mutations. Twenty percent of patients had KRAS mutations and seven percent had ALK rearrangements. Furthermore, 10% of the patients had MET amplifications. After responding to EGFR tyrosine kinase inhibitors (TKIs) initially, patients with EGFR mutations developed resistance, which was often linked to subsequent T790M mutations (Table 2).

Table 2: Genetic Mutations and Drug Resistance

Genetic Mutation	Prevalence (n=128)	Associated Resistance
EGFR	35%	T790M mutation
ALK	7%	Secondary resistance mutations
KRAS	20%	G12C, G12V mutations
MET Amplification	10%	Resistance to EGFR TKIs

Drug-resistant cancers have markedly altered DNA methylation and histone acetylation patterns, according to epigenetic modification analysis. Forty percent of the resistant patients had tumor suppressor genes such RASSF1A and CDKN2A hypermethylated. These individuals also showed hypoacetylation of histones H3 and H4, which is suggestive of transcriptional inhibition. As shown in figure 1, these epigenetic changes promoted drug resistance by silencing important genes involved in cell cycle control and apoptosis.



Figure 1: Epigenetic Modifications in Drug-Resistant Tumors

One important factor contributing to medication resistance was the tumor microenvironment. Resistant tumors showed elevated expression of extracellular matrix (ECM) components and high numbers of cancer-associated fibroblasts (CAFs). Furthermore, immunological profiling revealed a higher than expected concentration of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), which are known to inhibit anti-tumor immunity and promote resistance (Figure 2).



Figure 2: Tumor Microenvironment Characteristics

Of the 128 patients, 32% had targeted treatment determined by molecular profiling, and 68% got first-line chemotherapy. The median progression-free survival (PFS) was eight months, and the overall response rate (ORR) was 45%. After receiving EGFR TKI treatment for EGFR mutations, 70% of patients had an initial ORR; however, 50% of these patients acquired resistance in a median of 10 months. Table 3 summarizes the ORR of 60% for patients treated with ALK inhibitors whose ALK rearrangements resulted in resistance in 30% of cases after a year.

Table 3: Treatment Response and Survival

Parameters		**Value (n=128)**
Treatment Type	Overall Response Rate (ORR)	45%
	Median Progression-Free Survival (PFS)	8 months
EGFR Mutation Response to EGFR TKIs	Initial ORR	70%
	Median Time to Resistance	10 months
ALK Rearrangement Response to ALK Inhibitors	Initial ORR	60%
	Median Time to Resistance	12 months

MET amplification (OR = 2.8, 95% CI: 1.2-4.6, p = 0.002), hypermethylation of CDKN2A (OR = 2.3, 95% CI: 1.1-4.5, p = 0.015), and EGFR T790M mutation (OR = 3.5, 95% CI: 1.8-6.8, p < 0.001) were shown to be significant predictors of treatment resistance by multivariate logistic regression analysis. Table 4 indicates that Kaplan-Meier survival analysis revealed that patients with drug-resistant NSCLC had a substantially lower median overall survival (OS) of 14 months compared to 22 months in patients without resistance (log-rank p < 0.001).

Table 4: Predictors of Drug Resistance (Multivariate Logistic Regression Analysis)

Factor	**Odds Ratio (OR)**	**95% Confidence Interval (CI)**	**p-value**
EGFR T790M Mutation	3.5	1.8-6.8	<0.001
MET Amplification	2.8	1.2-4.6	0.002
Hypermethylation of CDKN2A	2.3	1.1-4.5	0.015

Potential treatment approaches to combat medication resistance were also investigated in this investigation. Preclinical models demonstrated the potential of combination therapy that target several pathways, such as EGFR TKIs in combination with MET inhibitors, which resulted in a significant delay in the development of resistance. Clinical studies are anticipated to provide further information. Immunotherapy using immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, has shown promise in surmounting resistance caused by the tumor microenvironment.

Discussion

The results of this study confirm the important roles of genetic, epigenetic, and microenvironmental variables in the mechanisms of treatment resistance in NSCLC and are consistent with other studies on these topics [14]. Our findings showing 35% of patients had EGFR mutations

are in line with previous research that has shown the frequency of these mutations and their effect on treatment outcomes [15]. Notably, the T790M mutation is a major cause of resistance to EGFR tyrosine kinase inhibitors (TKIs). Likewise, the identification of MET amplifications and ALK rearrangements in subgroups of patients adds credence to the idea that certain genetic changes drive resistance and need tailored treatment approaches. A considerable percentage of drug-resistant cancers were shown to have epigenetic alterations, such as hypoacetylation of histones and hypermethylation of the tumor suppressor genes CDKN2A and RASSF1A. These results support earlier studies that epigenetic modifications may silence important regulatory genes, allowing cancer cells to proliferate and survive in the face of treatment [16]. The finding that CDKN2A hypermethylation was present in 40% of resistant individuals highlights the need of investigating epigenetic therapy to undo these changes and regain medication sensitivity.

The importance of the tumor microenvironment in drug resistance, as shown by elevated expression of extracellular matrix (ECM) components and large numbers of cancer-associated fibroblasts (CAFs), is consistent with the increasing knowledge that the microenvironment may have a major impact on treatment response [17]. The need for combinatorial strategies that target the tumor cells and their supporting milieu in order to overcome resistance is highlighted by the increased prevalence of immunosuppressive cells in resistant tumors, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Patients with drug-resistant nonsmall cell lung cancer NSCLChad worse outcomes than those without resistance, according to our study's treatment response and survival statistics. Novel treatment techniques are urgently needed, as shown by the fact that patients with resistance had a median overall survival (OS) of 14 months, whereas those without had an OS of 22 months. The 8-month median progression-free survival (PFS) that was reported is consistent with other research that found low response durability in the presence of resistance mechanisms [18].

Preclinical models demonstrating the effectiveness of combination therapy targeting several resistance mechanisms point to a viable avenue for further investigation. Clinical studies investigating combinations of immune checkpoint inhibitors and tumor microenvironment-mediated resistance are necessary due to the potential of these inhibitors to overcome resistance [16,18]. Our results suggest that enhancing patient outcomes requires a personalized medicine strategy that includes molecular profiling and customized therapy.

Limitations and Future Directions

Despite its thoroughness, this research has a number of shortcomings. Despite being shown to be statistically significant, the sample size of 128 individuals could not adequately represent the heterogeneity of NSCLC, which might restrict how broadly applicable our results can be. Furthermore, the research was only carried out at one institution, which might create bias in the selection process and restrict the data' generalizability to larger groups. Certain studies that rely on retrospective data may potentially introduce biases about the completeness and correctness of the data. To verify these results, future research should strive to include bigger, more varied patient groups and make use of multi-center cooperation. Furthermore, further research is necessary to fully understand other possible mechanisms of drug resistance, such as metabolic changes and non-coding RNAs, even though our work focused on important genetic, epigenetic, and environmental components. It is crucial to carry out further research on the creation and clinical evaluation of combination treatments and new drugs that target these resistance mechanisms. Deeper understanding of the dynamic nature of resistance and guidance for the development of more efficient, individualized treatment methods will come from longitudinal studies tracking the development of drug resistance over time and in response to various treatment regimens.

Conclusion

This research clarified the intricate processes behind medication resistance in by emphasizing significant genetic alterations, epigenetic changes, and micro environmental variables. Our results highlight the need of tailored treatment strategies that include targeted medications and molecular profiling in order to overcome resistance and enhance patient outcomes. To confirm these findings in more varied and bigger groups and to investigate new treatment approaches, further study is needed.

References

1. Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting?. Frontiers in oncology. 2018 Jul 24;8:267. https://doi.org/10.3389/fonc.2018.00267

2. Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacology & therapeutics. 2020 Feb 1;206:107438.

3. Terlizzi M, Colarusso C, Pinto A, Sorrentino R. Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacology & therapeutics. 2019 Oct 1;202:140-8. https://doi.org/10.1016/j.pharmthera.2019.06.005

4. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature medicine. 2021 Aug;27(8):1345-56.

5. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of hematology & oncology. 2019 Dec 9;12(1):134. https://doi.org/10.1186/s13045-019-0818-2

6. Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small

cell lung cancer (NSCLC)-novel approaches and future outlook. Molecular Cancer. 2020 Dec;19:1-5.

7. Min HY, Lee HY. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Archives of pharmacal research. 2021 Feb;44(2):146-64. https://doi.org/10.1007/s12272-021-01312-y

8. Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, Huang TH. Identification of withaferin A as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers. 2019 Jul 17;11(7):1003.

9. Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Research. 2019 Feb 15;79(4):689-98. https://doi.org/10.1158/0008-5472.CAN-18-1281

10. Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers. 2022 Jul 8;14(14):3337. https://doi.org/10.3390/cancers14143337

11. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer treatment reviews. 2018 Apr 1;65:1-0.

12. Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, Guarini C, De Santis P, Perrone M, Fedele P. The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies. Pharmaceutics. 2023 May 27;15(6):1604. https://doi.org/10.3390/pharmaceutics15061604

13. Eser PÖ, Jänne PA. TGFβ pathway inhibition in the treatment of non-small cell lung cancer. Pharmacology & therapeutics. 2018 Apr 1;184:112-30.

14. Halliday PR, Blakely CM, Bivona TG. Emerging targeted therapies for the treatment of non-small cell lung cancer. Current oncology reports. 2019 Mar;21:1-2. https://doi.org/10.1007/s11912-019-0770-x

15. Florczuk M, Szpechcinski A, Chorostowska-Wynimko J. miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: current perspectives. Targeted oncology. 2017 Apr;12:179-200.

16. Ramisetty S, Kulkarni P, Bhattacharya S, Nam A, Singhal SS, Guo L, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Pisick E. A systems biology approach for addressing cisplatin resistance in non-small cell lung cancer. Journal of Clinical Medicine. 2023 Jan 11;12(2):599. https://doi.org/10.3390/jcm12020599

17. Walsh RJ, Soo RA. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Therapeutic advances in medical oncology. 2020 Jul;12:1758835920937902.

18. Tong CW, Wu WK, Loong HH, Cho WC, To KK. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer letters. 2017 Oct 1;405:100-10. https://doi.org/10.1016/j.canlet.2017.07.023